Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 and DC-NK Cells in Pediatric Solid Tumors
NCT03815084Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Modality
- Whole Cell Cancer Vaccines, Lymphokine-Activated Killer Cells, Dendritic Cell Vaccines
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by Allife Medical Science and Technology. Primary endpoint: Treatment Related Adverse Events at 1 year. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03815084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815084.